<DOC>
	<DOCNO>NCT01742299</DOCNO>
	<brief_summary>The purpose study allow continue use imatinib patient imatinib treatment Novartis-sponsored , Oncology Clinical Development &amp; Medical Affairs ( CD &amp; MA ) study benefit treatment judge investigator .</brief_summary>
	<brief_title>Study Allow Access Imatinib Patients Who Are Imatinib Treatment Novartis-sponsored Study Are Benefiting From Treatment Judged Investigator</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patient currently enrol Novartissponsored , Oncology Clinical Development &amp; Medical Affairs study receive imatinib fulfil requirement parent study . 2.Patient currently benefit treatment imatinib , determine investigator . 3 . Patient demonstrate compliance , assess investigator , parent study protocol requirements.4 . Willingness ability comply schedule visit , treatment plan study procedure . 5 . Written inform consent obtain prior enrol rollover study . 1 . Patient permanently discontinue imatinib treatment parent study due unacceptable toxicity , noncompliance study procedure , withdrawal consent reason . 2 . Patient participate Novartis sponsor combination trial imatinib dispense combination another study medication patient still receive combination therapy . 3 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hcG laboratory test . 4 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception study 30 day final dose imatinib . Male patient must use highly effective contraception study 30 day final dose imatinib . Highly effective contraception define either : Total abstinence ( line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male sterilization ( least 6 month prior enrol ) . For female patient study vasectomized male partner sole partner patient . Use combination two follow ( a+b a+c , b+c ) : 1 . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception . 2 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) 3 . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository Women consider postmenopausal child bear potential 12 month natural ( spontaneous ) amenorrhea appropriate clinical profile ( e.g . age appropriate , history vasomotor symptom ) surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week prior enrol . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment consider child bear potential . If study patient become pregnant suspect pregnant study within 30 day final dose imatinib , investigator need inform immediately ongoing study treatment imatinib stop</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Glivec/Gleevec</keyword>
	<keyword>CML</keyword>
	<keyword>GIST</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>